Revenue
2023
2024
2025
Eupraxia Pharmaceuticals Inc. (EPRX)
Price$8.38Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — |
| Research & development | $21.3M | $16.1M | $20.4M | $13.6M |
| Operating expenses | $38.4M | $27.0M | $27.8M | $17.6M |
| Operating income | −$38.4M | −$27.0M | — | −$17.6M |
| EBITDA | −$38.3M | −$25.0M | — | −$17.9M |
| Net income | −$38.6M | −$25.5M | −$28.2M | −$18.5M |
| Basic EPSper basic share | -$1.03 | -$0.76 | -$1.17 | -$0.96 |
| Diluted EPSper diluted share | -$1.03 | -$0.76 | -$1.17 | -$0.96 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Beutel, Goodman & Co Ltd. | 3.63M |
Affinity Asset Advisors, LLC | 1.65M |
Balyasny Asset Management L.P. | 1.35M |
Vivo Capital, LLC | 1.35M |
SCOTIA CAPITAL INC. | 1.34M |
PFM Health Sciences, LP | 1.21M |
GREAT POINT PARTNERS LLC | 1.2M |
Jupiter Topco LLC | 1.05M |
Rubric Capital Management LP | 867.42K |
Ikarian Capital, LLC | 809.74K |
Woodline Partners LP | 746.86K |
Point72 Asset Management, L.P. | 730.28K |
AMERIPRISE FINANCIAL INC | 711.02K |
Redmile Group, LLC | 611.4K |
Seven Fleet Capital Management LP | 610.79K |
UBS Group AG | 519.21K |
CITADEL ADVISORS LLC | 502.01K |
MILLENNIUM MANAGEMENT LLC | 441.59K |
Alyeska Investment Group, L.P. | 375K |
PICTON MAHONEY ASSET MANAGEMENT | 360.88K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data